Dibutilftalato/toxicidade; Poluentes Ambientais/toxicidade; Plastificantes/toxicidade; Animais; Regulação da Expressão Gênica/efeitos dos fármacos; Genômica; Humanos; Medição de Risco/métodos

3 beta-hydroxysteroid dehydrogenase/delta-5­delta-4 isomerase type II; ADME; AGD; ALDH2; AR; BBDR model; CNPs; CYP2D6; Cyp11a1/P450scc; Cyp17a1; Cyp2b1; Cyp3a1; DBP; DEG; DEHP; D­R; EDC; Endocrine disrupting chemical; GO; Hsd3b; IRIS; Insl3; Integrated Risk Information System; MBP; MOA; Male development; NIEHS; NOAEL; National Institute of Environmental Health Sciences; PBPK modeling; Phthalates; RT-PCR; Risk assessment; SD; STAR; Scarb1; Science to Achieve Results; Sprague­Dawley; Star; T; TD; TDS; TGx; TK; Testosterone; Toxicogenomic; U.S. Environmental Protection Agency; UDP glucuronosyltransferase 2B1; UF(H); US EPA; Ugt2b1; WOE; absorption, distribution, metabolism, and excretion; aldehyde dehydrogenase-2; androgen receptor; anogenital distance; biologically based dose­response model; copy number polymorphisms; cytochrome P450 2D6; cytochrome P450, family 11, subfamily a, polypeptide 1; cytochrome P450, family 17, subfamily a, polypeptide 1; cytochrome P450, family 2, subfamily b, polypeptide 1; cytochrome P450, family 3, subfamily a, polypeptide 1; di-(2-ethylhexyl) phthalate; dibutyl phthalate; differentially-expressed gene; dose­response; endocrine disrupting chemical; gene ontology; insulin-like 3; mode of action; monobutyl phthalate; no observed adverse effect level; physiologically based pharmacokinetic modeling; reverse transcription-polymerase chain reaction; scavenger receptor class B, member 1; steroidogenic acute regulatory protein; testicular dysgenesis syndrome; testosterone; toxicodynamics; toxicogenomic; toxicokinetics; uncertainty factor for uncertainty in extrapolating animal data to humans (i.e., interspecies uncertainty) (http://www.epa.gov/IRIS/); weight-of-evidence